in 2012, advair was part of a larger civil settlement agreement between glaxosmithkline (gsk) and the united states, in which gsk agreed to pay $1.043 billion; the united states said that gsk promoted off-label uses of advair and paid kickbacks to healthcare professionals to sell this drug, among others.